Novel treatment strategies to inhibit vessel and tumor growth following hematopoietic stem cell transplantation
Katarina Riesner, Linda Hammerich, Charité - Universitätsmedizin Berlin, Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie
Inhalte
For a variety of malignant hematological diseases, hematopoietic stem cell transplantation is the only curative treatment option and the last hope for many leukemia patients. However, more than half of the patients die within the first two years after transplantation because of tumor relapse or graft versus host disease (GVHD). Therefore, there is an urgent medical need for novel treatment strategies in this area for new therapeutic approaches. We identified a new approach by therapeutically inhibiting specific genes which are expressed during GVHD-related pathological angiogenesis. In disease-specific mouse models we will test the efficacy of this novel approach in inhibiting tumor growth by using state-of-the art methods as immune status assessment via flow cytometry and immunofluorescence microscopy. The course will be divided in practical lab sessions, data analysis sessions and background seminars, concluding with a final data presentation in an internal symposium.
Requirements for participation: Since this course is a continuation of the WS 24/25 course, "Analyzing the Efficacy of Novel Treatment Strategies in Inhibiting Tumor Growth Following Hematopoietic Stem Cell Transplantation," participants must have taken and completed the aforementioned course before enrolling in the SS 25 session.
Dates:
1. Termin (Introduction/Kick-off) 24.04.25 12-14 Uhr
Exact dates will be determined in collaboration with the students during the kick-off meeting and throughout the ongoing experiments.
Room/Meeting Place:
Seminarraum 2.0026 (2.OG),
Forum 4, Augustenburger Platz 1
13353 Berlin, Campus Charité Virchowklinikum
Kontakt
katarina.riesner@charite.de, linda.hammerich@charite.de